Dr. Soheil Meshinchi

powered by
COS Expertise®
Fred Hutchinson Cancer Research Center
Pediatric Hematology and Oncology
Clinical Research Division
Associate Member
Seattle Children's Hospital
Division of Pediatric Hematology and Oncology
Department of Pediatric Oncology/ Stem Cell Transplantation
Associate Professor and Attending Physican
University of Washington
Pediatric Hematology and Oncology
Department of Pediatric Hematology/ Stem Cell Transplantation
Associate Professor
Professional Headshot of Soheil Meshinchi

Mailing Address

Fred Hutchinson Cancer Research Center
Clinical Research Division
1100 Fairview Ave. N.
Mail Stop D5-368
Seattle, Washington 98109
United States

Contact Information

Phone: (206) 667-4077
Fax: (206) 667-4310
smeshinc@fhcrc.org

Qualifications

Fellowship Training, University of Washington, Pediatic Hematology and Oncology, 2000.
Fellowship Training, Fred Hutchinson Cancer Research Center, Pediatic Hematology and Oncology, 2000.
Residency Training, Johns Hopkins Hospitals, Pediatrics, 1997.
M.D., Wayne State University, 1994.
Ph.D., University of Michigan, Pharmacology/Protein Biochemistry, 1990.

Expertise and Research Interests

A. Clinical Expertise:
- Identification and therapy of high-risk leukemias
- Stem cell transplantation in leukemias
- Therapy of relapsed AML
- Targeted therapy in pediatric AML

B. Laboratory Interests:
Biologic and Clinical Significance of Receptor Tyrosine Kinase Mutations and their role in the Pathogenesis of AML
- Prelavence and clinical significance of FLT3 and other RTK mutations in AML
- Biologic consequence of RTK mutations in normal and malignant hematopoiesis
Identification of novel markers of high risk disease in AML.
- Using state of the art molecular biologic techniques including gene expression profiling, proteomics, and real-time RT-PCR , putative high risk markers are being identified and validated in a large cohort of pediatric and adult AML patients. This information will be used to create a patient-specific risk profile to be used in treatment assignement
Minimal Residual Disease (MRD) as a marker of high-risk disease in Pediatric AML
- Evaluation of flow cytometric evidence of MRD and its correlation with outcome
- Evaluation of molecular evidence of MRD and correlation with outcome
- Stem Cell origin of myeloid leukemias and role of RTK mutations in the evolution of AML
- Role of activating mutations of the signal transduction pathway in myeloid malignancies

Keywords

COS Keywords:

Biochemistry, Proteins, Cell Transplantation, Clinical Research Or Studies, Hematology, Leukemia, Oncology, Pediatrics, Pharmacology, Receptors, Stem Cells.

Additional Terms:

Pediatric Acute Myeloid Leukemia, Tyrosine Kinase Receptor Function.

Languages

(Reading, Writing, Speaking)

Farsi: (Functional, Functional, Fluent)

Memberships

American Society of Clinical Oncology
American Society of Hematology
Children's Oncology Group Myeloid Disease Committee
Childrens Oncology Group

Honors and Awards

Jose Carrera's International Leukemia Fellow, Jose Carrera's Leukemia Foundation, Fred Hutchinson Cancer Research Center, Molecular Pathogenesis of FLT3 Mutations in AML
Child Health Research Center Scholar, National Institutes of Health (NIH), University of Washington
COG Young Investigator Award, Childrens Oncology Group

Previous Positions

Acting Instructor, Fred Hutchinson Cancer Research Center
Assistant Professor and Attending Physician, Children's Hospital and Regional Medical Center, Pediatric Hematology and Oncology
Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division, Pediatric Oncology/Stem Cell Transplantation
Assistant Professor, University of Washington, School of Medicine, Pediatrics, Pediatric Hematology and Oncology, Stem Cell Transplantation

Funding Received

  • National Institutes of Health (NIH): R01, Administrative Supplement to current R01, Biology and Prognostic Implications of FLT3 Mutations in AML, 2009 to 2010.
  • Children's Oncology Group: Molecular Assessment of Minimal Risk in Acute Promyelocytic Leukemia, 2009 to 2010.
  • National Institutes of Health (NIH): TARGET Supplement to the Children's Oncology Group Chair's Grant, 2009 to 2011.
  • Fred Hutchinson Cancer Research Center and National Institute of Health: Pilot Study Single Cell Genomic Profiling in Cancer, 2009 to 2010.
  • Fred Hutchinson Cancer Research Center and CCEH: Pilot Study Validating Susceptibility Genes for Acute Myeloid Leukemia, 2009 to 2010.
  • Children's Oncology Group: COG Scientific Committee Chair, 2009 to 2010.
  • National Cancer Institute/ National Children's Cancer Foundation: Biomarkers for Risk Identification and Risk-Based Therapy in Pediatric AML, 2008 to 2010.
  • Seattle Children's: Alterations of DNA Repair Pathway in Regulating Homologous Recombination in AML, 2008 to 2010.
  • Seattle Children's: Biologic and Clinical Implications of a s-SHIP Expression in Pediatric Leukemias, 2007 to 2010.
  • National Institutes of Health (NIH): RO-1, Biology and Prognostic Implications of FLT3 Mutations in AML, 2005 to 2010.
  • National Institutes of Health (NIH): R-21, Accurate Prediction of Early Relapse in Pediatric AML, 2004 to 2006.
  • Children's Oncology Group: COG Translational Research Award, 2004 to 2006.
  • National Institutes of Health (NIH): R-21, Prognostic Implications of FLT3 Mutations in AML, 2003 to 2006.
  • Children's Oncology Group: COG Young Investigator Award, 2001 to 2002.
  • NIH/University of Washington: Child Health Research Center Award, 2000 to 2002.
  • Jose Carreras Leukemia Foundation: Jose Carrera's International Leukemia Foundation, Young Investigator Award, 2000 to 2003.
  • National Institutes of Health/FHCRC: K-12 Translational Research Award, 2000 to 2002.

Publications

  • Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP. (2006) Clinical implications of FLT3 mutations in pediatric AML, Blood, Aug 15; [Epub ahead]
  • Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, Meshinchi S, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA. (2006) A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies., Leukemia, 20 (7), 1295-7
  • Children's Oncology Group; Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM. (2006) Children's Oncology Group; Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM., Blood, 108 (1), 74-80
  • Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA. (2006) No abstract Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML., Blood, 108 (1), 400
  • Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, Meshinchi S. (2006) Abstract FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia., Blood, Jun 29; [Epub ahead]
  • Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP. (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia., Blood, 107 (9), 3724-6
  • Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hahlen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia., Blood, 19 (9), 1536-42
  • Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP, Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia, Blood, 104(10), 3058-63, Nov 2004 Abstract
  • Loh ML, Reynolds MG, Vattikuti S, Gerbing RB, Alonzo TA, Carlson E, Cheng JW, Lee CM, Lange BJ, Meshinchi S, Children's Cancer Group, PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group, Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.k., 18(11), 1831-4, Nov 2004 Abstract
  • Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV, Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes, Blood, 104(9), 2646-54, Nov 2004 Abstract
  • Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS, Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse, Pediatr Blood Cancer, 43(5), 571-9, Oct 2004 Abstract
  • Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D, Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition, Blood, 104(6), 1841-9, Sep 2004 Abstract
  • Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM, Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis, Blood, 103(6), 2325-31, Mar 2004 Abstract
  • Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, Radich JP, Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia, British Journal of Haematology, 124(4), 481-4, Feb 2004 Abstract
  • Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE, Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia, Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation., 9(11), 706-13, Nov 2003 Abstract
  • Meshinchi S, Smith FO, Arceci RJ, Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia, Current Oncology Reports, 5(6), 489-97, Nov 2003 Abstract
  • Johnston DL, Meshinchi S, Opheim KE, Pallavicini MG, Feusner J, Woods WG, Lange BJ, Radich JP, Bernstein ID, Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia, British Journal of Haematology, 123(3), 431-5, Nov 2003 Abstract
  • Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F, FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance, Blood, 102(7), 2387-94, Oct 2003 Abstract
  • Meshinchi S, Stirewalt DL, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP, Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia, Blood, 102(4), 1474-9, Aug 2003 Abstract
  • Stirewalt DL, Meshinchi S, Radich JP, Molecular targets in acute myelogenous leukemia, Blood Reviews, 17(1), 15-23, Mar 2003 Abstract
  • Meshinchi S, Thomson B, Finn LS, Leisenring W, Green C, Radich JP, Loken M, Hawkins D, Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia, Journal of Pediatric Hematology/oncology : Official Journal of the American Society of Pediatric Hematology/oncology., 23(9), 585-90, Dec 2001 Abstract
  • Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP, FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia, Blood, 97(11), 3589-95, Jun 2001 Abstract
  • Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP, Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia, Blood, 97(1), 89-94, Jan 2001 Abstract
  • Meshinchi S, Stancato LF, Gordon BM, Jones KW, Pratt WB, Purification of the endogenous glucocorticoid receptor stabilizing factor, Biochemistry, 30(35), 8617-22, Sep 1991 Abstract
  • Hutchison KA, Matic G, Meshinchi S, Bresnick EH, Pratt WB, Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor, The Journal of Biological Chemistry, 266(16), 10505-9, Jun 1991 Abstract
  • Scherrer LC, Dalman FC, Massa E, Meshinchi S, Pratt WB, Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex, The Journal of Biological Chemistry, 265(35), 21397-400, Dec 1990 Abstract
  • Pratt WB, Dalman FC, Meshinchi S, Scherrer LC, The relationship between glucocorticoid receptor binding to Hsp90 and receptor function, Nippon Naibunpi Gakkai Zasshi, 66(12), 1185-97, Dec 1990 Abstract
  • Meshinchi S, Matic G, Hutchison KA, Pratt WB, Selective molybdate-directed covalent modification of sulfhydryl groups in the steroid-binding versus the DNA-binding domain of the glucocorticoid receptor, The Journal of Biological Chemistry, 265(20), 11643-9, Jul 1990 Abstract
  • Meshinchi S, Sanchez ER, Martell KJ, Pratt WB, Elimination and reconstitution of the requirement for hormone in promoting temperature-dependent transformation of cytosolic glucocorticoid receptors to the DNA-binding state, The Journal of Biological Chemistry, 265(9), 4863-70, Mar 1990 Abstract
  • Pratt WB, Sanchez ER, Bresnick EH, Meshinchi S, Scherrer LC, Dalman FC, Welsh MJ, Interaction of the glucocorticoid receptor with the Mr 90,000 heat shock protein: an evolving model of ligand-mediated receptor transformation and translocation, Cancer Research, 49(8 Suppl), 2222s-2229s, Apr 1989 Abstract
  • Meshinchi S, Pratt WB, Evidence that removal of an endogenous metal that stabilizes the untransformed glucocorticoid receptor in cytosol allows ligand-independent receptor transformation, Journal of Steroid Biochemistry, 34(1-6), 315-7, 1989 Abstract
  • Meshinchi S, Grippo JF, Sanchez ER, Bresnick EH, Pratt WB, Evidence that the endogenous heat-stable glucocorticoid receptor stabilizing factor is a metal component of the untransformed receptor complex, The Journal of Biological Chemistry, 263(32), 16809-17, Nov 1988 Abstract
  • Sanchez ER, Meshinchi S, Schlesinger MJ, Pratt WB, Demonstration that the 90-kilodalton heat shock protein is bound to the glucocorticoid receptor in its 9S nondeoxynucleic acid binding form, Molecular Endocrinology (baltimore, Md.), 1(12), 908-12, Dec 1987 Abstract
  • Sanchez ER, Meshinchi S, Tienrungroj W, Schlesinger MJ, Toft DO, Pratt WB, Relationship of the 90-kDa murine heat shock protein to the untransformed and transformed states of the L cell glucocorticoid receptor, The Journal of Biological Chemistry, 262(15), 6986-91, May 1987 Abstract
  • Tienrungroj W, Meshinchi S, Sanchez ER, Pratt SE, Grippo JF, Holmgren A, Pratt WB, The role of sulfhydryl groups in permitting transformation and DNA binding of the glucocorticoid receptor, The Journal of Biological Chemistry, 262(15), 6992-7000, May 1987 Abstract

Profile Details

Last Updated: 11/19/2009

COS Expertise ID #976897
Reference this profile directly: http://myprofile.cos.com/smeshinc